Tariquidar: QLTI started 2 double-blind North American and European Phase III trials of tariquidar as an adjunctive treatment in combination with first-line che

QLT Inc. (QLTI; TSE:QLT), Vancouver, B.C. Product: Tariquidar (XR9576) Business: Cancer Therapeutic category: Adjunct Target: Pgp ( MDR1) Description: P-glycoprotein multidrug resistance pump inhibito...